Xilaz Concentrate For Solution for Infusion
PDF Leaflet Revision Date: 06 December 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic colorectal cancer and adjuvant treatment of stage III colon cancer.
Dosage (summary)
85 mg/mu00b2 IV every 2 weeks for adults.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; effective contraception required.
Key Drug Interactions
- Caution with QT prolonging drugs
- Caution with drugs causing rhabdomyolysis
Contraindications
- Hypersensitivity to oxaliplatin
- Breastfeeding
- Bone marrow failure
- Myelosuppression
- Peripheral sensory neuropathy
- Severe renal impairment
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Neutropenia
- Peripheral neuropathy
Counselling Points
- Avoid cold exposure post-infusion
- Monitor for neurological symptoms
- Report severe gastrointestinal symptoms
- Discuss fertility preservation options
Serious warnings
- Serious hypersensitivity reactions
- Neurological toxicity
- Risk of intestinal ischaemia
- QT prolongation
Important Disclaimer
The Xilaz Concentrate For Solution for Infusion professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
